Figure 2. TLI/ATS + BMT induces generation of distinct subsets of CD11b⁺ myeloid recipient populations in major GVHD target organs.

(A) Representative FACS plots of CD11b and Gr-1 staining of gated H-2K^b-negB220^neg cells in spleens of recipients at day 6 after conditioning and BMT from WT C57BL/6 donors. Three distinct CD11b⁺ populations are indicated by colored gates. Percentage of cells is given adjacent to each gate. red gate: H-2K^b-negB220^negCD11b⁺Gr-1^high (Gr-1^high); green gate: H-2K^b-negB220^negCD11b⁺Gr-1^int (Gr-1^int); blue gate: H-2K^b-negB220^negCD11b⁺Gr-1^low (Gr-1^low). (B) Mean ± SEM absolute number of Gr-1^high (left panel), Gr-1^int (middle panel), and Gr-1^low (right panel) cells in spleen of recipients receiving TBI800/ATS (n = 4), TBI400/ATS (n = 7) or TLI/ATS (n = 8) followed by BM + SPL from WT C57BL/6 donors. (C) Mean ± SEM absolute number Gr-1^high (left column panels), Gr-1^int (middle column panels), and Gr-1^low (right column panels) cells in MLN (top row), liver (middle row), and colon (bottom row) of WT BALB/c recipients from B. TBI: total body irradiation; TLI: total lymphoid irradiation; ATS: anti-thymocyte serum; BM: 50 × 10⁶ WT C57BL/6 donor bone marrow cells; SPL: 60 × 10⁶ WT C57BL/6 donor spleen cells; TBI800, TBI400: cGy cumulative doses of TBI.